1. Project 2020 is an Integrated Biobanking Platform with comprehensive Electronic
Health Record for bio-pharma industry and national healthcare system.
The Market
Global market of Healthсare Information Systems is estimated at $53.8B by 2014, with
CAGR 16.1%. Growth of biobanking platforms segment is driven by development of
personalized medicine, enhanced security and compliance requirements, collaborative
studies, tight linkage of biospecimens with clinical and molecular data. Russian market
size is $0.7B. Target customers are biotech and pharmaceutical companies, clinicians,
clinical trial leaders and clinical research organizations. Shortcomings of local legacy
systems (Smart Delta Systems, Complex Medical Information Systems, Post Modern
Technology, AksiMed, Medline-Soft, to name few) include outdated client-server
architecture, limited scalability, locked business logic, no support of biobanking, eHealth
or mHealth systems.
The Company
Company/Business Concept
Carbon Valley is focused on Real World Data collection and analytics for healthcare
industries using SaaS model. It plans to develop Perinatal Care module to its existing bio-
IT system in 2014. Pre-loaded health and age-specific disease profiles with embedded
clinical decision support triggers are aimed at families, neonatologists and physicians.
Drug exposure profiles and other actionable data will be generated for bio-pharma and
healthcare regulators. Personal subscription fee $4-$50/month. Business subscription fee
for system access, biospecimen collection and management, social media listening,
patient recruitment, data aggregation, export or analysis will be calculated on case-by-
case basis.
Project/Technology
Project 2020 aims to build a national network of biobanks and perinatal EHR systems that
allows patients, doctors, hospitals, labs and biobanks to securely input and exchange
health record data, in compliance with privacy protection laws and R&D data quality
requirements. It will also generate anonymized data for complex analysis needed in
exploratory, translational or clinical research. The new integrated biobanking method is
proposed, wherein samples and associated medical data will be deposited across the
federated network and labeled using a unique bio-ID number. In partnership with the
Center of Perinatal Medicine, national laboratory chain In-Vitro, VR Foundation (USA)
and World Health Academy (Switzerland).
Expected advantages of the technology over main competitors
Designed from the ground-up by researchers, it saves bio-pharma up to 10% of the
typical R&D budget and cuts up to 3 yrs off the product development cycle. Projected
national healthcare savings are over $84M/yr. There are no direct competitors in Russia.
Average user cost savings compared to integration of competing services in the US are
over $125K/yr: i.e. cost of shared biobanking service provided by Genetic Alliance
Biobank starts at $60K/yr, typical cost of bio-IT platform lease starts at $65K/yr.
Current R&D Status
A disease-specific EHR platform for patient-centred data aggregation and biosample
management dubbed CloudBank is built and already in use by VR Foundation (USA),
including cloud architecture, user profiles, individual workspaces, medical record temp-
late, clinical methods, biobanking protocol, social media data collection & analytics tools.
Intellectual Property
IP will be protected via patents and copyrights in Russia and the US.
Team
The team of 4 is led by Yan Valle, CEO, Co-Founder. 20yrs in business consulting, high-
tech and biotech. CEO of VR Foundation (USA). Graduate of Moscow Tech. Univ. of
Radio Engineering, Electronics & Automation (MIREA), Engineer. MBA. Torello Lotti, Head
of R&D, MD. Prof. of Dermatology at Marconi Univ., Italy. Philippe Delesalle. Business
Dev. 10yrs of design/programming scalable networking and analytics solutions. Alexander
Sigov, Advisor. Academician of Russian Acad.of Sc, Dr.Phys.Sc. Prof. at MIREA.
Investment Opportunity
Seeking $2M funding structured as $1M of equity investment and $1M Skolkovo grant
(application being developed) for creating a national network of biobanks and perinatal
EHR systems in Russia.
Carbon Valley
Legal entity in the form of "ООО" (Ltd), Moscow, Russia
Business Status
Proof of concept
- Product development
Revenues, before breakeven
Revenues, profitable
Skolkovo Status
Project
Stage
 Stage 1 (to do proof of concept)
 Stage 2 (to do early testing)
 Stage 3 (to do late testing)
 Stage 4 (entry to market)
Cluster IT
Foresights
(priority R&D
directions)
 New technologies for network
infrastructure, linking physical
and virtual objects, through the
collection, processing and
analysis of data;
 Development of new methods
and algorithms for collecting,
storing and mining of big data.
Grant
Financing
$1M grant application is being
developed
Market
Target Market
size
$40.4B (global)
$0.7B (Russia)
Target Market
Healthcare Information Systems,
including: EHR, eHealth and
mHealth
Financials
$M 2011 12 13* 14*
Revenues - - - -
Net Income - - - -
Free Cash
Flow - - - -
Tangible
Assets - - - -
* forecast
Patents
Received -
Pending -
PCT -
Funding background
Financing Round Round A
Invested to-date $0.3M
Expected pre-money
valuation
tbd
Funding Needs,
current round
$2M
Equity investment
needed
$1M
Expected share of the
investor
tbd
Contact details
Carbon
Valley
Yan Valle, CEO
+7 (903) 728-8252
yan@carbon-valley.org
Skolkovo
Investment
Office
Dmitry Schigolev
+7 (495) 967-0148 (x2390)
dschigolev@sk.ru
Sep 5
2013